IOP Reduction After Anecortave Acetate Injection in Glaucoma Patients

Federal University of São Paulo

Status

Unknown

Conditions

Glaucoma

Intraocular Pressure

Treatments

Drug: Anterior Juxtascleral Depot of Anecortave Acetate

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00533962

C-01

Details and patient eligibility

About

Introduction: Ocular administration of glucocorticoids is a common and effective treatment for several ocular diseases. However it is often complicated with the elevation of intraocular pressure (IOP). Anecortave acetate (AA) is an analog of cortisol acetate and lacks the typical anti-inflammatory and immunosuppressive properties of glucocorticoids. The effect of its anterior juxtascleral depot (AJD) injection has been evaluated in cases of glaucoma caused by intravitreal triamcinolone acetonide, presenting impressive results. The purpose of this study is to evaluate the efficacy and safety of the AA injection as a possible antiglaucoma treatment alternative. Methods: A prospective clinical study will be carried out including 30 glaucoma patients (30 eyes). After inclusion each patient will receive a single AJD injection of 30 mg of AA in the selected eye. Main outcome measure include: intraocular pressure at 1st day, 7th day, 1st, 2nd and 3rd months.

Enrollment

30 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Advanced glaucoma cases with surgery or cyclophotocoagulation indication (IOP over 25 mmHg)
Patients should be under maximum tolerated medication
Low best corrected visual acuity (worse than 20/100)

Exclusion criteria